MedTrace Logo

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

NCT05258331 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-03-18

No results posted yet for this study

Summary

Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis

Conditions

Interventions

GENETIC

CT303

1. Cohort 1 : Single-dose administration, intravenous injection * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg * Dose 2 : 2.0\*10\^6 cells/kg * Dose 3 : 3.0\*10\^6 cells/kg 2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4) * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg * Dose 2 : 2.0\*10\^6 cells/kg * Dose 3 : 3.0\*10\^6 cells/kg

Sponsors & Collaborators

  • GC Cell Corporation

    lead INDUSTRY

Principal Investigators

  • Seongjin Jo · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2024-08-30
Completion
2024-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258331 on ClinicalTrials.gov